Versameb: Funding, Investors & Team (Sep 2026)
Versameb AG is a preclinical-stage biopharmaceutical company located in Basel, Switzerland managed by an experienced scientific and business pharmaceutical industry team. The company’s focus is the development of novel RNA-based therapeutics. Versameb’s proprietary VERSagile technology platform enables efficient development of functional mRNA molecules for customized protein expression and modification in multiple disease areas with high unmet medical need.
Versameb has raised $6.0M across 1 funding round on record, the most recent an undisclosed round of $6.0M announced in Jul 2020.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Versameb Company Profile and Key Stats
Latest funding round on record: Jul 2020.
Versameb Funding Rounds
Versameb Founders and Leadership Team
Contact details for the Versameb team: 1 of 1 has an email address on file.
Start 14-day free trial →Versameb Funding Compared to Other Biotechnology Startups
Versameb's latest round of $6.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Versameb in Biotechnology and Basel
Companies Similar to Versameb
Adaptyv Biosystems developing a protein engineering platform using cell-free synthetic biology and…
At Immitra Bio, we are developing a unique genetic medicine platform that combines two of the most powerful…
compliag is providing agile solutions for regulated industries, including the licencing, manufacturing and…
MoonLake Immunotherapeutics is a biopharmaceutical company in the clinical stage that is developing new…
Isospec Analytics SA is a life science company that aims at simplifying molecular identification. We are…
Cria Technologies reinvents cold-chain transport with high-vacuum insulation technology that offers…
Precise Health is a phage therapy platform that specialises in improving and treating bacterial infections to…
AC Immune is a biopharmaceutical company based in Switzerland that is currently in the clinical stage. They…
AlveoliX provides in-vitro solutions based on proprietary and unique organ-on-chip technologies aimed at…
Combioxin SA is clinical-stage biotech company developing innovative anti-virulence drugs to treat severe…
MindMaze is a digital neurotherapeutic platform that provides digital assessments and therapeutics to treat…
Neurosoft Bioelectronics is developing next-generation soft implantable electrodes to interface with the…
Versameb Funding FAQs
What does Versameb do?
Versameb AG is a preclinical-stage biopharmaceutical company located in Basel, Switzerland managed by an experienced scientific and business pharmaceutical industry team. The company’s focus is the development of novel RNA-based therapeutics. Versameb’s proprietary VERSagile technology platform enables efficient development of functional mRNA molecules for customized protein expression and modification in multiple disease areas with high unmet medical need.
How much funding has Versameb raised?
Versameb has raised $6.0M across 1 round on record. The most recent is an undisclosed round of $6.0M announced in Jul 2020.
When did Versameb last raise funding?
Versameb's most recent funding round on record is an undisclosed round of $6.0M, announced in Jul 2020.
Who is the CEO of Versameb?
Friedrich Metzger is listed as CEO at Versameb.
Where is Versameb headquartered?
Versameb is based in Basel, Basel-Stadt, Switzerland.
How many employees does Versameb have?
Versameb is in the 11-50 employee band.
How does Versameb's funding compare to other Biotechnology startups?
Versameb's latest round of $6.0M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Versameb Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Versameb is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.